Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Other Accumulated Expenses (2021 - 2025)

Relay Therapeutics (RLAY) has disclosed Other Accumulated Expenses for 5 consecutive years, with $463000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 76.73% to $463000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $463000.0, a 76.73% decrease, with the full-year FY2025 number at $463000.0, down 76.73% from a year prior.
  • Other Accumulated Expenses was $463000.0 for Q4 2025 at Relay Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $26.9 million in Q3 2022 to a low of $396000.0 in Q4 2021.
  • A 5-year average of $8.7 million and a median of $1.7 million in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: soared 6504.04% in 2022, then plummeted 96.96% in 2024.
  • Relay Therapeutics' Other Accumulated Expenses stood at $396000.0 in 2021, then skyrocketed by 6504.04% to $26.2 million in 2022, then crashed by 95.4% to $1.2 million in 2023, then soared by 65.28% to $2.0 million in 2024, then plummeted by 76.73% to $463000.0 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Other Accumulated Expenses are $463000.0 (Q4 2025), $1.1 million (Q3 2025), and $609000.0 (Q2 2025).